Drug Treatment of Lipid Disorders
Arteriosclerosis of the coronary and peripheral vasculature is the leading cause of death among men and women in the United States 1 and worldwide. 2 In 1992, for example, cardiovascular disease accounted for 38 percent of deaths from all causes among men and 42 percent of all deaths among women in...
Gespeichert in:
Veröffentlicht in: | The New England journal of medicine 1999-08, Vol.341 (7), p.498-511 |
---|---|
1. Verfasser: | |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 511 |
---|---|
container_issue | 7 |
container_start_page | 498 |
container_title | The New England journal of medicine |
container_volume | 341 |
creator | Knopp, Robert H |
description | Arteriosclerosis of the coronary and peripheral vasculature is the leading cause of death among men and women in the United States
1
and worldwide.
2
In 1992, for example, cardiovascular disease accounted for 38 percent of deaths from all causes among men and 42 percent of all deaths among women in Washington State
3
; nationwide, the mortality rate for cardiovascular disease is approximately 50 percent.
4
Mechanisms of Atherogenesis
Central to the pathogenesis of arteriosclerosis is the deposition of cholesterol in the arterial wall.
5
,
6
Nearly all lipoproteins are involved in this process, including cholesterol carried by very-low-density lipoprotein (VLDL),
7
,
8
remnant lipoprotein, . . . |
doi_str_mv | 10.1056/NEJM199908123410707 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_223958828</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>43775997</sourcerecordid><originalsourceid>FETCH-LOGICAL-c430t-19b84fbe597536263ae0f15abb43cf289825841a1dae03e010d1cd78ca623a333</originalsourceid><addsrcrecordid>eNp9kM1OwzAQhC0EoqXwBEgoIG4osOu1E_uI2vKnAJdyjpzEQamapNjJgbcnKJXggNjLHPabGWkYO0W4RpDRzcvy6Rm11qCQk0CIId5jU5REoRAQ7bMpAFehiDVN2JH3axgOhT5kEwQhMIJ4ys4Xrn8PVs6arrZNF7RlkFTbqggWlW9dYZ0_Zgel2Xh7stMZe7tbruYPYfJ6_zi_TcJcEHQh6kyJMrNSx5IiHpGxUKI0WSYoL7nSiksl0GAxPMgCQoF5EavcRJwMEc3YxZi7de1Hb32XrtveNUNlyjlpqRRXA0QjlLvWe2fLdOuq2rjPFCH9XiX9Y5XBdbaL7rPaFr884wwDcLkDjM_NpnSmySv_w2mMhIQBuxqxuvZpY9f1v61fszZysg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>223958828</pqid></control><display><type>article</type><title>Drug Treatment of Lipid Disorders</title><source>MEDLINE</source><source>New England Journal of Medicine Current</source><source>EZB-FREE-00999 freely available EZB journals</source><source>ProQuest Central UK/Ireland</source><creator>Knopp, Robert H</creator><contributor>Wood, Alastair J.J.</contributor><creatorcontrib>Knopp, Robert H ; Wood, Alastair J.J.</creatorcontrib><description>Arteriosclerosis of the coronary and peripheral vasculature is the leading cause of death among men and women in the United States
1
and worldwide.
2
In 1992, for example, cardiovascular disease accounted for 38 percent of deaths from all causes among men and 42 percent of all deaths among women in Washington State
3
; nationwide, the mortality rate for cardiovascular disease is approximately 50 percent.
4
Mechanisms of Atherogenesis
Central to the pathogenesis of arteriosclerosis is the deposition of cholesterol in the arterial wall.
5
,
6
Nearly all lipoproteins are involved in this process, including cholesterol carried by very-low-density lipoprotein (VLDL),
7
,
8
remnant lipoprotein, . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJM199908123410707</identifier><identifier>PMID: 10441607</identifier><identifier>CODEN: NEJMAG</identifier><language>eng</language><publisher>Boston, MA: Massachusetts Medical Society</publisher><subject>Anion Exchange Resins - adverse effects ; Anion Exchange Resins - therapeutic use ; Biological and medical sciences ; Cardiovascular disease ; Cardiovascular Diseases - etiology ; Cholesterol ; Clofibrate - adverse effects ; Clofibrate - therapeutic use ; Diet ; Female ; General and cellular metabolism. Vitamins ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use ; Hyperlipidemias - complications ; Hyperlipidemias - diet therapy ; Hyperlipidemias - drug therapy ; Hypolipidemic Agents - adverse effects ; Hypolipidemic Agents - therapeutic use ; Lipids ; Male ; Medical sciences ; Mortality ; Niacin - adverse effects ; Niacin - therapeutic use ; Pharmacology. Drug treatments ; Risk Factors</subject><ispartof>The New England journal of medicine, 1999-08, Vol.341 (7), p.498-511</ispartof><rights>Copyright © 1999 Massachusetts Medical Society. All rights reserved.</rights><rights>1999 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c430t-19b84fbe597536263ae0f15abb43cf289825841a1dae03e010d1cd78ca623a333</citedby><cites>FETCH-LOGICAL-c430t-19b84fbe597536263ae0f15abb43cf289825841a1dae03e010d1cd78ca623a333</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJM199908123410707$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/223958828?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,2759,2760,26103,27924,27925,52382,54064,64385,64389,72469</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1916450$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10441607$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Wood, Alastair J.J.</contributor><creatorcontrib>Knopp, Robert H</creatorcontrib><title>Drug Treatment of Lipid Disorders</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>Arteriosclerosis of the coronary and peripheral vasculature is the leading cause of death among men and women in the United States
1
and worldwide.
2
In 1992, for example, cardiovascular disease accounted for 38 percent of deaths from all causes among men and 42 percent of all deaths among women in Washington State
3
; nationwide, the mortality rate for cardiovascular disease is approximately 50 percent.
4
Mechanisms of Atherogenesis
Central to the pathogenesis of arteriosclerosis is the deposition of cholesterol in the arterial wall.
5
,
6
Nearly all lipoproteins are involved in this process, including cholesterol carried by very-low-density lipoprotein (VLDL),
7
,
8
remnant lipoprotein, . . .</description><subject>Anion Exchange Resins - adverse effects</subject><subject>Anion Exchange Resins - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Cardiovascular disease</subject><subject>Cardiovascular Diseases - etiology</subject><subject>Cholesterol</subject><subject>Clofibrate - adverse effects</subject><subject>Clofibrate - therapeutic use</subject><subject>Diet</subject><subject>Female</subject><subject>General and cellular metabolism. Vitamins</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</subject><subject>Hyperlipidemias - complications</subject><subject>Hyperlipidemias - diet therapy</subject><subject>Hyperlipidemias - drug therapy</subject><subject>Hypolipidemic Agents - adverse effects</subject><subject>Hypolipidemic Agents - therapeutic use</subject><subject>Lipids</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mortality</subject><subject>Niacin - adverse effects</subject><subject>Niacin - therapeutic use</subject><subject>Pharmacology. Drug treatments</subject><subject>Risk Factors</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kM1OwzAQhC0EoqXwBEgoIG4osOu1E_uI2vKnAJdyjpzEQamapNjJgbcnKJXggNjLHPabGWkYO0W4RpDRzcvy6Rm11qCQk0CIId5jU5REoRAQ7bMpAFehiDVN2JH3axgOhT5kEwQhMIJ4ys4Xrn8PVs6arrZNF7RlkFTbqggWlW9dYZ0_Zgel2Xh7stMZe7tbruYPYfJ6_zi_TcJcEHQh6kyJMrNSx5IiHpGxUKI0WSYoL7nSiksl0GAxPMgCQoF5EavcRJwMEc3YxZi7de1Hb32XrtveNUNlyjlpqRRXA0QjlLvWe2fLdOuq2rjPFCH9XiX9Y5XBdbaL7rPaFr884wwDcLkDjM_NpnSmySv_w2mMhIQBuxqxuvZpY9f1v61fszZysg</recordid><startdate>19990812</startdate><enddate>19990812</enddate><creator>Knopp, Robert H</creator><general>Massachusetts Medical Society</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope></search><sort><creationdate>19990812</creationdate><title>Drug Treatment of Lipid Disorders</title><author>Knopp, Robert H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c430t-19b84fbe597536263ae0f15abb43cf289825841a1dae03e010d1cd78ca623a333</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Anion Exchange Resins - adverse effects</topic><topic>Anion Exchange Resins - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Cardiovascular disease</topic><topic>Cardiovascular Diseases - etiology</topic><topic>Cholesterol</topic><topic>Clofibrate - adverse effects</topic><topic>Clofibrate - therapeutic use</topic><topic>Diet</topic><topic>Female</topic><topic>General and cellular metabolism. Vitamins</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</topic><topic>Hyperlipidemias - complications</topic><topic>Hyperlipidemias - diet therapy</topic><topic>Hyperlipidemias - drug therapy</topic><topic>Hypolipidemic Agents - adverse effects</topic><topic>Hypolipidemic Agents - therapeutic use</topic><topic>Lipids</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mortality</topic><topic>Niacin - adverse effects</topic><topic>Niacin - therapeutic use</topic><topic>Pharmacology. Drug treatments</topic><topic>Risk Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Knopp, Robert H</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Knopp, Robert H</au><au>Wood, Alastair J.J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Drug Treatment of Lipid Disorders</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>1999-08-12</date><risdate>1999</risdate><volume>341</volume><issue>7</issue><spage>498</spage><epage>511</epage><pages>498-511</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><coden>NEJMAG</coden><abstract>Arteriosclerosis of the coronary and peripheral vasculature is the leading cause of death among men and women in the United States
1
and worldwide.
2
In 1992, for example, cardiovascular disease accounted for 38 percent of deaths from all causes among men and 42 percent of all deaths among women in Washington State
3
; nationwide, the mortality rate for cardiovascular disease is approximately 50 percent.
4
Mechanisms of Atherogenesis
Central to the pathogenesis of arteriosclerosis is the deposition of cholesterol in the arterial wall.
5
,
6
Nearly all lipoproteins are involved in this process, including cholesterol carried by very-low-density lipoprotein (VLDL),
7
,
8
remnant lipoprotein, . . .</abstract><cop>Boston, MA</cop><pub>Massachusetts Medical Society</pub><pmid>10441607</pmid><doi>10.1056/NEJM199908123410707</doi><tpages>14</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0028-4793 |
ispartof | The New England journal of medicine, 1999-08, Vol.341 (7), p.498-511 |
issn | 0028-4793 1533-4406 |
language | eng |
recordid | cdi_proquest_journals_223958828 |
source | MEDLINE; New England Journal of Medicine Current; EZB-FREE-00999 freely available EZB journals; ProQuest Central UK/Ireland |
subjects | Anion Exchange Resins - adverse effects Anion Exchange Resins - therapeutic use Biological and medical sciences Cardiovascular disease Cardiovascular Diseases - etiology Cholesterol Clofibrate - adverse effects Clofibrate - therapeutic use Diet Female General and cellular metabolism. Vitamins Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Hyperlipidemias - complications Hyperlipidemias - diet therapy Hyperlipidemias - drug therapy Hypolipidemic Agents - adverse effects Hypolipidemic Agents - therapeutic use Lipids Male Medical sciences Mortality Niacin - adverse effects Niacin - therapeutic use Pharmacology. Drug treatments Risk Factors |
title | Drug Treatment of Lipid Disorders |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T20%3A26%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Drug%20Treatment%20of%20Lipid%20Disorders&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Knopp,%20Robert%20H&rft.date=1999-08-12&rft.volume=341&rft.issue=7&rft.spage=498&rft.epage=511&rft.pages=498-511&rft.issn=0028-4793&rft.eissn=1533-4406&rft.coden=NEJMAG&rft_id=info:doi/10.1056/NEJM199908123410707&rft_dat=%3Cproquest_cross%3E43775997%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=223958828&rft_id=info:pmid/10441607&rfr_iscdi=true |